DS-8273a + nivolumab

DS-8273a + nivolumab is a combination of two investigational monoclonal antibodies being studied for the treatment of advanced cancers, particularly unresectable Stage III or IV melanoma. DS-8273a is an agonistic anti-death receptor 5 (DR5, also known as TRAIL-R2) monoclonal antibody that selectively targets and eliminates myeloid-derived suppressor cells (MDSCs), which are immunosuppressive cells in the tumor microenvironment. By depleting MDSCs, DS-8273a may enhance anti-tumor immune responses. Nivolumab is a well-established anti-PD1 immune checkpoint inhibitor that blocks programmed death receptor 1 (PD1) on T-cells to promote immune-mediated tumor cell killing. The combination aims to improve cancer immunotherapy efficacy by both reducing immunosuppression and enhancing T-cell activity[1][2][4].

Brand names

nivolumab (Opdivo)

Other names

Anti-DR5 monoclonal antibodyAnti-DR-5 monoclonal antibodyAnti-DR 5 monoclonal antibodyTRAIL D5 antibodyTRAIL-R2 agonistic antibodyTRAIL-R-2 agonistic antibodyTRAIL-R 2 agonistic antibody